Baker Brothers Life Sciences Capital (GP), LLC
CIK 1307729 · last filed 2012-02-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.57B
Companies
14
Total Filings
62
Lifetime Open-Market Net
$533.25M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 7,639,436 | — | — | $173.92M | 11 | 2012-02-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 4,922,226 | — | — | $44.72M | 1 | 2012-02-03 |
| INCY | Director | 12,213,272 | $118.87 | $1.45B | $232.64M | 16 | 2012-01-17 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 5,077,676 | — | — | $0 | 1 | 2012-01-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 8,011,759 | — | — | $51.49M | 5 | 2011-08-25 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 6,112,357 | — | — | $0 | 1 | 2011-07-05 |
| BCRX | 10%+ Owner | 3,841,124 | $9.31 | $35.78M | $0 | 1 | 2011-07-05 |
| Seagen Inc. (SGEN) Delisted | Director | 11,119,820 | $228.74 | $2.54B | -$16.96M | 4 | 2010-05-27 |
| RPRX | 10%+ Owner | 1,345,866 | $59.15 | $79.61M | $1.78M | 1 | 2010-04-28 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 25,747 | $7.22 | $186.0K | -$8.70M | 6 | 2008-07-30 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 8,002,776 | — | — | $63.07M | 3 | 2008-05-27 |
| NEUROGEN CORP (NRGN) Delisted | Director | — | — | — | $0 | 1 | 2008-04-15 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 1,821,429 | — | — | -$7.7K | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 1,004,905 | — | — | -$8.69M | 6 | 2007-12-07 |
Recent Filings · Page 7 of 7
62 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-02-14 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +518,088 | $9.46M | EDGAR |
| 2007-02-01 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Buy (P) | +7,022,934 | $42.14M | EDGAR |
Showing 61–62 of 62
Prev
Page 7 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.